PSR Orphan Experts, Raremark announce rare disease tieup

London cityscape
London cityscape

The Netherlands-based orphan drug consulting and research company PSR Orphan Experts has signed a pact with Raremark, a new online service for families affected by rare disease, on a partnership designed to speed up the development of new treatments.

This new collab will use the companies’ complementary experience and capabilities to address the unique challenges involved in clinical research in orphan indications--which typically struggles with patient recruitment, given the small patient population for rare diseases.

London’s Raremark said it will engage families in the clinical trial process, helping them understand what taking part in a study means, and keeping them informed while participating in one.


Industry Insight Survey: Direct-to-Patient Distribution of Clinical Supplies

This industry survey seeks to gain insight on trial sponsors' perspective on offering a DTP option and their current level of awareness and understanding of any factors that may influence their ability to do so. The first 50 qualified respondents will receive a $5 Amazon gift card.

Meanwhile PSR will provide strategic and operational consulting, in addition to its traditional CRO services.

“Most of the 7,000 known rare diseases lack approved drugs, meaning that clinical trials may be the only opportunity for people affected to access treatments,” said Roger Legtenberg, CEO of PSR.

“The rare disease community is generally very active, but there is a need for increased awareness that clinical trials are an option. We believe Raremark’s approach of engaging rare disease patients and families will bring benefits for all involved in drug development.”

Julie Walters, Raremark’s founder, added: “We’re impressed by PSR’s genuine commitment to the patient community, its sole focus on orphan disease, and the high caliber of its management team and long-standing relationships with specialist research centers.”

-check out the release

Suggested Articles

German biopharma services company Sartorius is to spend three-quarters of a billion dollars to buy up Danaher’s life science portfolio.

Health organization NSF International is delving deeper into life sciences after buying up the majority stake of CRO Amarex Clinical Research.

As Covance changes up its leadership amid a change at the top of its parent company, one of its former execs has jumped ship to midsize rival CRO.